Edgar Filing: PORTOLA PHARMACEUTICALS INC - Form 8-K

PORTOLA PHARMACEUTICALS INC Form 8-K

Form 8-K August 09, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 9, 2016

Portola Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction

001-35935 (Commission

20-0216859 (IRS Employer

of incorporation)


File Number)

Identification No.)

Edgar Filing: PORTOLA PHARMACEUTICALS INC - Form 8-K

270 E. Grand Avenue

South San Francisco, California 94080 (Address of principal executive offices) (Zip Code) Registrant s telephone number, including area code: (650) 246-7300



- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition

On August 9, 2016, Portola Pharmaceuticals, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2016. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Form 8-K and the Exhibit attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Number 99.1 Press release entitled Portola Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update dated August 9, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 9, 2016

Portola Pharmaceuticals, Inc.

By: /s/ Mardi C. Dier Mardi C. Dier

Executive Vice President and Chief Financial

Officer

EXHIBIT INDEX

Number Description of Document

Press release entitled Portola Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update dated August 9, 2016.